Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
02:40aFDA approves Gilead cancer gene therapy; price set at $373,000
25
10/19[email protected] goes after $GILD on $373K price of Yescarta. Calls on Trump &..
3
10/19  
10/19  
10/19We discuss $GILD CAR-T approval, up next on @PowerLunch
1
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
2
10/1935 Stocks Moving In Thursday's Mid-Day Session
3
10/1950 most #liquid, high #RelativeStrength #stocks in the #market $AABA $BABA $B.. 
10/19Gilead Kite's treatment becomes first FDA approved CAR-T therapy #KitePharma,.. 
10/19Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug  
10/19Gilead receives FDA approval for Kite's breakthrough CAR-T therapy for .. 
10/19Gilead shares climb after its L.A.-area Kite unit gets FDA approval for lymph.. 
10/19LIVE: Gilead gains 4% after FDA approves lymphoma drug $GILD -
4
10/19Gilead: A New Cancer Drug! Great…But You Still Overpaid for Kite  
10/19Gilead cell-therapy drug Yescarta gets FDA approval
1
10/19ICYMI following Wed's mkt close: Another CAR-T rides into town as FDA approva.. 
10/19Gilead gets FDA go-ahead for second CAR-T . Read more about the $12 bln deal ..
4
10/19WATCH: Stocks we're watching today - $VZ, $AXP, $NKE, $APRN, $GILD
3
10/19Gilead Sciences Yescarta Drug Approved By FDA  
10/19A Kite-Gilead #cancer treatment that's part of 'a big new field of medicine' .. 
10/19Gilead: A New Cancer Drug! Great?But You Still Overpaid for Kite  
10/19FDA approves Gilead cancer gene therapy; price set at $373,000  
10/19The FDA approves the Gilead's Yescarta lymphoma cancer therapy drug
4
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
2
10/19Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-c.. 
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
2
10/19Pharmalot.. Pharmalittle.. Good Morning.. Novo pins hopes on newly approved d.. 
10/19On The Fly: Pre-market Movers $VZ $DHR $BX $DGX $LLNW $URI $GILD $BLFS $ONCE .. 
10/19#Stocks to Watch today: $VZ, $AXP, $NKE, $APRN, $GILD
5
10/19Gilead Jumps After FDA Approves Its Kite-Acquired CAR-T Drug
1
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
3
10/19ICYMI: $GILD breaks into CAR-T market with Yescarta approval
1
10/19morning game plan. $ADBE $GILD $EBAY $UAL to watch our am meeting live ??
1
10/19Gilead Sciences shares bolstered after FDA approval validates Kite Pharma mer.. 
10/19Morning Movers: Gilead Gains, Nike Drops, Philip Morris Tumbles  
10/19  
10/19Pre-mkt movers/news | via CNBC $ADBE $UAL $EBAY $APRN $TSM $TRV $VZ $NKE $BX..
1
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
113
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
9
10/19U.S. FDA approves Gilead cancer gene therapy; price set at $373,000
3
10/1922 Stocks Moving In Thursday's PreMarket
3
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
13
10/19Buying in Gilead (Kite Pharma) spreads to Juno, up 2% premarket  
10/19Gilead Sciences's buy rating reiterated at Berenberg Bank. $96.00 PT.  
10/19Verizon Communications, Gilead Sciences, Alcoa Corp, PayPal Holdings - PRE-MA.. 
10/19$GILD (+2.0% pre) FDA follows through with a groundbreaking OK for Yescarta, ..
1
10/19Gilead faces patent battle with Juno over Yescarta, says Morgan Stanley $JUNO..
1
10/19"He refused The Handmaid’s Tale, too – presumably because those Gilead robes ..
1
10/19We discuss $GILD Yescarta approval, coming up on @SquawkCNBC 
10/19Berenberg Bank Releases a Buy Rating on Gilead Sciences $GILD  
More tweets
Qtime:303
Financials ($)
Sales 2017 25 890 M
EBIT 2017 15 933 M
Net income 2017 10 607 M
Debt 2017 14 814 M
Yield 2017 2,59%
P/E ratio 2017 10,18
P/E ratio 2018 11,99
EV / Sales 2017 4,69x
EV / Sales 2018 5,18x
Capitalization 107 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,0 $
Spread / Average Target 4,1%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912
EXELIXIS, INC.84.64%8 091